India, May 19 -- Co-Diagnostics Inc. (CODX) is positioning itself for rapid response as global health authorities escalate alerts around a new Ebola outbreak, completing the development of its assay strategy for a Bundibugyo virus (BDBV) assay designed for fast, decentralized detection.
The company's update follows the World Health Organization's declaration of a public health emergency of international concern after BDBV cases were confirmed in the Democratic Republic of the Congo and Uganda. As of May 17, 2026, officials reported eight laboratory-confirmed cases, 246 suspected cases, and 80 suspected deaths in DRC, along with two confirmed cases and one death in Uganda.
Co-Diagnostics CEO Dwight Egan said the company is prepared to move...